The Latest

  • White flags bearing Novo Nordisk's logo are seen against a blue sky.
    Image attribution tooltip
    Courtesy of Novo Nordisk
    Image attribution tooltip

    Will the real Ozempic please stand up? Lilly, Novo face uphill counterfeit battle

    Weight loss market leaders are warning patients and healthcare providers about the risks associated with knockoff versions of their popular obesity meds — and taking legal action.  

  • Moderna vax
    Image attribution tooltip
    Jens Schluete via Getty Images
    Image attribution tooltip
    Q&A

    Can Moderna’s COVID-flu combo shot improve flagging vaccination rates?

    A COVID and flu duo could ease manufacturing and administration, potentially driving higher vaccination rates, said Moderna’s VP of North American medical affairs.

  • Faye Feller, executive vice president, chief medical officer, Geron
    Image attribution tooltip
    Permission granted by Geron
    Image attribution tooltip

    After 33 years, Geron’s first approval marks a turn in Nobel-winning science

    The decades-long story of how a first-in-class blood cancer treatment went from bench to bedside.

  • Exterior sign of Bristol-Myers Squibb
    Image attribution tooltip
    Permission granted by Bristol-Myers Squibb
    Image attribution tooltip

    Ahead of its upcoming decision date, a competitor takes aim at KarXT

    The FDA isn’t slated to render a decision about BMS and Karuna’s potential breakthrough schizophrenia med until September — but a biotech is already hoping to be hot on its heels.  

  • A 3D illustration of a ribosome as part of an biological cell constructing a messenger RNA molecule.
    Image attribution tooltip
    Christoph Burgstedt via Getty Images
    Image attribution tooltip
    Q&A // First 90 Days

    After an obesity deal with Novo, Omega’s new business head is on the hunt for more partners

    With a career focused on striking deals, Kaan Certel is hoping to lead the Flagship-backed biotech with an mRNA platform into its next phase of growth. 

  • window woman
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    3 windows of opportunity in women’s health

    Despite a recent surge of interest, the femtech and women’s health markets are far from reaching their full potential.

  • Historic main building of the National Institutes of Health
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    NIH-funded trials fall flat on diversity goals

    Many clinical trials aren’t meeting enrollment inclusion checkpoints — and some aren’t even setting targets, according to a recent OIG report.

  • An illustration of B cells producing antibodies
    Image attribution tooltip
    Love Employee via Getty Images
    Image attribution tooltip

    New data showcase promise, growing pains of CAR-T in autoimmune disease

    One expert described trial results presented at EULAR last week as “unprecedented.” But reports of relapses in some patients drew questions about the therapies’ ultimate potential.

  • Junk yard
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    Avoiding the pharma ‘junk pile’ with launch readiness, pipeline rigor and ‘quick kills’

    Drug launches have underperformed expectations at a high rate, and pharmas need to get better at thinning the pipeline to make room for the real wins, says a life sciences consultant.

  • Brain scans of a person with Alzheimer's are seen in this conceptual image.
    Image attribution tooltip
    digicomphoto via Getty Images
    Image attribution tooltip

    The hunt for the brain’s biomarkers

    How Roche is finding better ways to diagnose brain conditions like Alzheimer’s and Parkinson’s disease.

  • Paxlovid
    Image attribution tooltip
    Joe Raedle via Getty Images
    Image attribution tooltip

    Pfizer’s Paxlovid flunks long COVID study as researchers uncover the condition’s deep toll

    While researchers gain ground understanding long COVID’s impact, viable treatments could still be a long way off.

  • A 3D illustration showing amyloid plaques in brain tissue
    Image attribution tooltip
    Dr_Microbe via Getty Images
    Image attribution tooltip

    Lilly’s adcomm win shows amyloid and tau will likely dominate Alzheimer’s — for now

    Lilly is the latest to approach the coveted Alzheimer’s approval, but a slate of drugmakers are lining up clinical trials in amyloid and tau to take a shot at improving patient outcomes.

  • Close up of conference room with glasses of water on the table with papers, armchairs and a large window.
    Image attribution tooltip
    Igor Kutyaev via Getty Images
    Image attribution tooltip
    Making Moves

    Regenxbio CEO to step down after 15 years

    Kenneth Mills will become chair of the gene therapy developer's board while Curran Simpson, the current chief operating officer, will take his place as company head.

  • MDMA
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Despite adcomm rejection, Lykos CEO sees future for MDMA drug

    Although the rebuff makes approval “a bit more challenging,” Lykos is moving forward with the psychedelic-based treatment for PTSD.

  • digital blue pill on computer chip background
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Behind the powerful computations, AI’s role in pharma is still beset by challenges

    Small biotechs are saving time and money leveraging AI to develop new drugs, but incomplete data and disease complexity remain hurdles for the space.

  • Image attribution tooltip
    Christopher Furlong via Getty Images
    Image attribution tooltip

    As Big Pharma places bigger bets on ADCs, here’s where the field is headed next

    With more drugmakers getting into the antibody-drug conjugate game, emerging innovations signal a bright future for the technology.

  • FDA headquarters with sign in foreground
    Image attribution tooltip
    Sarah Silbiger via Getty Images
    Image attribution tooltip

    FDA’s platform designation aims to ease R&D pain points

    A new program creates approval pathways for multiple drugs developed on the same platform. 

  • Exterior sign of Bristol-Myers Squibb
    Image attribution tooltip
    Permission granted by Bristol-Myers Squibb
    Image attribution tooltip

    Behind Big Pharma’s layoffs — is there an end in sight?

    A slew of major companies, including BMS, have announced cost-cutting measures in recent months. What will it take to turn the tide?

  • gambling chips
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Pharma’s R&D gamble: picking pipeline winners in a risky field

    How leaders from biotech, Big Pharma and the investment world know when they've found the right candidate or company to back.

  • City of Hope Helford Clinical Research Hospital in Duarte, California
    Image attribution tooltip
    Permission granted by City of Hope
    Image attribution tooltip

    A ‘widening gap’ in access to new cancer meds drives efforts from City of Hope and Bristol Myers

    Cancer care is improving so quickly that receiving newer medications can be difficult — City of Hope’s wide oncology network and a 10-year commitment from Bristol Myers Squibb offer some solutions.

  • FibroBiologics CEO Pete O'Heeron at the opening bell for the Nasdaq
    Image attribution tooltip
    Permission granted by FibroBiologics
    Image attribution tooltip
    Biotech Spotlight

    Regenerative cell therapy biotech uses IPO to blast into human trials

    Bucking conventional fundraising, FibroBiologics’ CEO Pete O’Heeron explains why the biotech company bet on themselves in the public market.

  • A wall showing a Merck & Co. logo in Kenilworth, New Jersey
    Image attribution tooltip
    Courtesy of Merck & Co.
    Image attribution tooltip

    Merck and Moderna’s cancer vaccine snags a clinical win in a field decades old

    Cancer vaccines are taking off in the clinic, and a partnership between Merck and Moderna is at the forefront of a new wave of immunotherapy.

  • brand name drugs
    Image attribution tooltip
    Christopher Furlong via Getty Images
    Image attribution tooltip

    What’s in a drug name? More than you might think.

    From regulatory restrictions to evocative letter strings, branded drug naming is both an art and a science. We break down the process.

  • Medicine capsules on blue racing lines
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Q&A

    In an era of big patent losses, drug launches need years of runway

    Jim Lang, CEO of Eversana, explains the shifting commercial environment and how past drug launch failures are informing the future.

  • Image attribution tooltip
    Justin Sullivan via Getty Images
    Image attribution tooltip

    After two Big Pharma deals, Nimbus looks to keep the hits coming

    With the billion-dollar-plus deals under its belt with Gilead and Takeda, the biotech’s CEO explains where the company is going next.